Drug Profile
OPM 3023
Alternative Names: OPM-3023Latest Information Update: 09 Jun 2015
Price :
$50
*
At a glance
- Originator Bionetworks
- Developer onepharm; The Forsyth Institute
- Class Anti-inflammatories
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Periodontitis; Rheumatoid arthritis
Most Recent Events
- 03 Mar 2011 Investigation of locally administered formulation in Periodontitis in Austria (unspecified route, controlled release)